Key result
Unexplained week-to-week variation of BNP and NT-proBNP was low in stable chronic heart failure patients (15% and 8%, respectively), supporting their use for disease monitoring.
Why the study?
What is the week-to-week unexplained variation of BNP and NT-proBNP in stable chronic heart failure patients?
Observational (n=20)
What is the week-to-week unexplained variation of BNP and NT-proBNP in stable chronic heart failure patients?
Unexplained week-to-week variation of BNP and NT-proBNP is low in stable chronic heart failure patients, supporting their utility for disease monitoring.
Low unexplained BNP/NT-proBNP variation supports monitoring in stable HF; challenges prior high-variation concerns but leaves open need for trial confirmation.
BACKGROUND: The usefulness of brain-natriuretic-peptide (BNP) and N-terminal-pro-brain-natriuretic-peptide (NT-proBNP) for monitoring of chronic heart failure (CHF) patients has been questioned because of high levels of unexplained variation. AIMS: Week-to-week total variance (CV(T)), unexplained variation (CV(I)), reference change values (RCV), index of individualities (IOI) and number of samples (N) with week-to-week intervals needed to estimate the underlying homeostatic set point (+/-15%) for BNP and NT-proBNP were calculated in pre-specified stable CHF patients. METHODS AND RESULTS: We measured plasma concentrations of BNP and NT-proBNP, clinical and laboratory variables in 20 CHF patients with a 7-days interval. Only patients considered to be in steady state were included. The CV(I) was 15% (BNP) and 8% (NT-proBNP). CV(T) was 16% (BNP) and 8% (NT-proBNP) and RCV was 43% (BNP) and 23% (NT-proBNP). IOI was 0.14 for BNP and 0.03 for NT-proBNP and N was 1 for BNP and 1 for NT-proBNP. CONCLUSIONS: Our data demonstrate that unexplained variation of BNP and NT-proBNP is low in CHF patients during steady state, which is a prerequisite for the use of these peptides for monitoring of the disease.
No takes yet. Share an insight, caveat, or question.
Schou et al. (2006) conducted an observational in Chronic heart failure (n=20). BNP and NT-proBNP monitoring was evaluated on Week-to-week unexplained variation (CVI) and total variance (CVT). Unexplained week-to-week variation of BNP and NT-proBNP was low in stable chronic heart failure patients (15% and 8%, respectively), supporting their use for disease monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: